A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors

Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer.

(2010) DJ Slamon et al.   CANCER RESEARCH

Increased Epistaxis with Use of Ezetimibe/Simvastatin

(2009) Bansari Shah et al.   ANNALS OF PHARMACOTHERAPY

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

(2009) Thomas E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

chest tumors

(2008)   ANNALS OF ONCOLOGY

gynecological cancer

(2008)   ANNALS OF ONCOLOGY

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

(2008) Guru Sonpavde et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS